摘要
Abstract
Objective To determine the response rate,time to disease progression,survival,and safety profile of the therapeutic effects of Gemcitabine combinded with Docetaxel on patients with advanced hepatocellular carcinoma. Methods Forty-two patients with advanced hepatocellular carcinoma were enrolled from February 2006 to February 2010. Chemotherapy dose and method of setting: Docetaxel 30 mg/m2, Gemcitabine 800 mg/m2 intravenously over 30 minutes on days 1 and 8. 21 days for one cycle,two cycles were evaluated. Results Whole group of 42 patients total effective rate was 21. 4%, with an additional 47. 6% of patients with stable disease,for a disease control rate of 69. 0%. ,complete response rate was 0 (0/42),partial remission rate was 21. 4% (9/42), stable was 47. 6% (20/42), progress was 31. 0% (13/42). The median time to progression was 4. 1 months (95% confidence interval,2. 14-7. 26 months), median survival time was 9. 2 months (95% confidence interval,4. 25-18. 12 months). No treatment-related death,this chemotherapy combination was generally well tolerated. Decline in peripheral blood granulo-cytes,thrombocytopenia,mild anemia, gastrointestinal reactions, fatigue and occasional diarrhea and rash were commonly observed but were easily managed without discontinuing further treatment. Conclusion The significant antitumor activity combined with a mild toxicity profile seen from this study argues that Gemcitabine and Docetaxel chemotherapy may benefit patients with advanced hepatocellular carcinoma. This regimen warrants further evaluation in a randomized study with survival and quality of life end points.关键词
晚期肝细胞癌/吉西他滨/多西紫杉醇/联合化疗Key words
Advanced hepatocellular carcinoma/Gemcitabine/Docetaxel/Chemotherapy分类
医药卫生
